Article Information
History
- June 30, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Kathleen M. Andersen, PhD, MSc1,*,
- Matthew A. Brouillette, MPH1,
- Kanae Togo, PhD2,
- Kosuke Tanabe, PhD2,
- Benjamin T. Carter, PhD3,
- Matthew T. Kent, MS3,
- Yingjie Ding, MS3,
- Daniel Curcio, MD1,
- Verna Welch, PhD, MPH1,
- Leah J. McGrath, PhD1,
- Bushra Ilyas, PhD1 and
- Shuhei Ito, PhD2
- 1Pfizer Inc., 66 Hudson Boulevard East, New York, New York, United States, 10001
- 2Pfizer Japan Inc., 3-22-7 Yoyogi, Shibuya-ku, Tokyo, Japan, 151-8589
- 3Genesis Research, 111 River Street Suite 1120, Hoboken, New Jersey, United States, 07030
- ↵*Corresponding author: Kathleen M. Andersen, PhD, MSc, Global Scientific Affairs Director, COVID-19 and Flu Chief Medical Affairs Office, Pfizer Inc. email: kathleen.andersen{at}pfizer.com